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Summary
Background: Exposure to acetylsalicylic acid (ASA) may exacerbate respiratory or
skin diseases or induce anaphylactoid reactions in apparently healthy individuals. We
wanted to evaluate the clinical and diagnostic utility of measuring ASA-induced 15-
hydroxyeicosatetraenoic acid (15-HETE) generation.
Methods: We performed a prospective single-blind study with 26 subjects undergoing
clinical evaluation and/or ASA provocation testing. We also included 12 control subjects.
Peripheral blood leukocytes were incubated with 500mM ASA and 15-HETE release was
measured by competitive ELISA.
Results: We found that 18 subjects were ASA-tolerant and 8 were ASA-intolerant. The
mean increase in 15-HETE in intolerant subjects was 34% and this was comparable to the
mean increase of 30% observed in ASA-tolerant subjects. A similar mean increase was also
observed in control subjects. The ROC calculation showed that the optimal diagnostic
threshold would be an increase of greater than 33%. However, the sensitivity of this
increase was only 63% and the speciﬁcity was 50%.
Conclusions: Our data suggest that further studies are needed before the ASA-induced
15-HETE test can be used in clinical practice.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Exposure to acetylsalicylic acid (ASA) and nonsteroidal
anti-inﬂammatory drugs (NSAIDs) may exacerbate nasal
and/or respiratory symptoms in sensitive individuals with
asthma, or cutaneous symptoms in patients with chronic
urticaria.1 Urticaria and angioedema may also occur in
apparently healthy individuals.2 At present, the mechanism
of intolerance is not fully understood. The diagnosis of ASA
intolerance can be conﬁrmed by patient history or with a
provocation test. The test usually takes 2 days and may be
associated with severe adverse reactions; thus, alternative
procedures with a higher safety proﬁle are highly desirable.
Therefore, in vitro methods are being developed. One such
method is the 15-hydroxyeicosatetraenoic acid (15-HETE)
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test. This test is based on previous reports suggesting that
the peripheral blood leukocytes from ASA-sensitive asthma
patients may be triggered in vitro with ASA to generate
increased amounts of (15-HETE).3–5 For this reason, we
conducted a prospective single-blind study on a limited
number of patients to evaluate the diagnostic sensitivity and
speciﬁcity of 15-HETE testing in a routine clinical setting.
Material and methods
We included 26 subjects (mean age 52 years; 18 women,
8 men) recruited for the assessment of hypersensitivity to
non-steroidal anti-inﬂammatory drugs. In 58% of subjects, a
placebo-controlled oral provocation test with up to 933mg
of ASA was performed, as previously described.2 We also
included 12 matched control subjects (mean age 51 years;
seven women, ﬁve men). A 15-HETE test was carried out and
analyzed as previously described.4 Brieﬂy, peripheral blood
leukocytes were incubated with 500 mM aspirin (Aspegic,
0954-6111$ – see front matter © 2011 Elsevier Ltd. All rights reserved.
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Fig. 1. Effect of ASA on increased generation of 15-HETE production in (A) ASA-tolerant and ASA-intolerant subjects, (B) subjects divided
according to their provocation test results and history evaluations, (C) subjects divided according to their clinical phenotypes.
Sanoﬁ-Synthe´labo, Quetigny, France) and 15-HETE release
was measured in cell supernatants with competitive ELISA
(Assay Designs Inc., Ann Arbor, MI, USA).
Results
We found that 18 subjects were ASA-tolerant and 8 subjects
were ASA-intolerant. Diagnosis was conﬁrmed by an ASA
provocation test in 11 out of 18 tolerant patients and four
out of eight intolerant ones. In others, the diagnosis was
based on a strongly positive history of ASA intolerance,
such as a clinical reaction clearly documented by a
physician or the notation of more than one event. In
the ASA-intolerant group, four subjects had asthma and/or
rhinitis; in these subjects the sensitivity was manifested as
exacerbation of nasal and/or respiratory symptoms; in the
other four subjects, the sensitivity manifested as urticaria-
angioedema, although none of them had previous chronic
respiratory or skin disease. In the ASA-tolerant group, six
subjects had asthma and/or rhinitis and two had chronic
urticaria. Peripheral blood leucocytes from ASA-tolerant,
ASA-intolerant, and control subjects generated similar
amounts of 15-HETE at baseline (7.69±1.36, 8.22±1.79,
and 10.5±1.43 pg/mL, respectively; P = 0.37). Preincubation
with ASA increased the generation of 15-HETE to 9.12±1.31,
9.64±1.79, and 12.5±1.41 pg/mL, respectively (P = 0.87).
In ASA-tolerant subjects the increase was 34%, which was
comparable to the 30% increase observed in ASA-intolerant
subjects (Fig. 1A, P = 0.81). Similarly, the mean increase
in control subjects was 27% (P = 0.87). No difference was
observed whether the subjects were divided according to
the ASA provocation results, anamnestic evaluation (Fig. 1B,
P 0.46), or analyzed according to different phenotypes.
Namely, both ASA-exacerbated respiratory disease (N = 4)
and the urticaria-angioedema subgroup (N = 4) showed
comparably low results (Fig. 1C, P 0.16). To establish
the sensitivity and speciﬁcity of the ASA-triggered 15-HETE
release, receiver operating curve (ROC) analysis was also
performed. The ROC curve area was 0.57 and the P value was
0.58. The optimal recalculated threshold for ASA-induced
15-HETE increase was > 33%, with a true positive rate of 63%
(sensitivity) and a false positive rate of 50% (speciﬁcity).
Discussion
Several in vitro assays have been proposed to conﬁrm
ASA sensitivity. Those methods are the basophil CD63
activation test,5–7 the ASA triggered release of Cys-LTs
from peripheral blood leukocytes,8,9 and the 15 HETE-
test.3,4,10 Previous publications give conﬂicting results on
the basophil activation test, with some authors showing
that ASA basophil testing is diagnostically useful,5 whereas
others show that it is not useful6 or that it is useful only
in a subgroup of subjects that experience anaphylactoid
reactions.6 Second, although the leukocytes of patients with
aspirin sensitivity produce higher amounts of Cys-LTs as
measured by CAST, the differences between ASA-intolerant
and ASA-tolerant subjects were merely quantitative and the
test’s sensitivity to detect ASA intolerance rarely exceeded
50%.8,9 Furthermore, because the predictive value of CAST
was also low,9 the test has limited clinical usefulness in the
diagnosis of ASA hypersensitivity.
15-HETE is a potential inﬂammatory mediator, although
the mechanisms leading to increased generation of 15-HETE
after in vitro incubation with ASA are not known. In addition
to 15-lipooxygenase, both COX-1 and COX-2 are capable
of synthesizing 15-HETE, and ASA treatment stimulates the
formation of 15-HETE by COX-2 (but not COX-1), although
it inhibits prostaglandin generation.3 The evidence in favor
of the use of 15-HETE testing is two reports from 200010
and 20033 that documented speciﬁc triggering of 15-HETE
generation by ASA in peripheral blood and nasal polyp
epithelial cells from intolerant asthma patients. The same
group then assessed the possible diagnostic value of ASA-
induced 15-HETE generation. In their third report from
2005,4 they suggested that the sensitivity and speciﬁcity
of 15-HETE testing to detect ASA intolerance in asthma
and rhinitis patients was high, reaching 80%. Unfortunately,
these results have not been reproduced by other research
groups to date.
In conclusion, we showed comparable and moderate
increases in 15-HETE after in vitro incubation with ASA in
ASA-tolerant and ASA-intolerant subjects and also in control
subjects. Therefore, we demonstrated limited usefulness
of ASA 15-HETE testing for the diagnosis of ASA sensitivity.
Further evaluation of the test in a larger number of well-
characterized patients is needed before the 15-HETE test
can be used in clinical practice.
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